Intranasal Drug Delivery Devices Market Size, Share, and Trends 2025 to 2034

The global intranasal drug delivery devices market size is calculated at USD 1.87 billion in 2025 and is forecasted to reach around USD 4.41 billion by 2034, accelerating at a CAGR of 10% from 2025 to 2034. The North America market size surpassed USD 660 million in 2024 and is expanding at a CAGR of 10.05% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.

Last Updated : June 2025  |  Report Code : 1253  |  Category : Healthcare  |  Format : PDF / PPT / Excel

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Intranasal Drug Delivery Devices Market 

5.1. COVID-19 Landscape: Intranasal Drug Delivery Devices Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Intranasal Drug Delivery Devices Market, By System

8.1. Intranasal Drug Delivery Devices Market Revenue and Volume Forecast, by System

8.1.1. Metered Dose

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Multi-Dose Systems

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Unit-Dose Systems

8.1.3.1. Market Revenue and Volume Forecast

Chapter 9. Global Intranasal Drug Delivery Devices Market, By Container

9.1. Intranasal Drug Delivery Devices Market Revenue and Volume Forecast, by Container

9.1.1. Non-Pressurized Containers

9.1.1.1. Market Revenue and Volume Forecast (Metered Dose)

9.1.2. Pressurized Containers

9.1.2.1. Market Revenue and Volume Forecast

Chapter 10. Global Intranasal Drug Delivery Devices Market, By Application 

10.1. Intranasal Drug Delivery Devices Market Revenue and Volume Forecast, by Application

10.1.1. Chronic Obstructive Pulmonary Disease (COPD)

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Rhinitis

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Cystic Fibrosis

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Nasal Congestion

10.1.4.1. Market Revenue and Volume Forecast

10.1.5. Asthma

10.1.5.1. Market Revenue and Volume Forecast

10.1.6. Others

10.1.6.1. Market Revenue and Volume Forecast

Chapter 11. Global Intranasal Drug Delivery Devices Market, By End User 

11.1. Intranasal Drug Delivery Devices Market Revenue and Volume Forecast, by End User

11.1.1. Ambulatory Surgical Centers

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Clinics

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Hospitals

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Others

11.1.4.1. Market Revenue and Volume Forecast

Chapter 12. Global Intranasal Drug Delivery Devices Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by System

12.1.2. Market Revenue and Volume Forecast, by Container

12.1.3. Market Revenue and Volume Forecast, by Application

12.1.4. Market Revenue and Volume Forecast, by End User

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by System

12.1.5.2. Market Revenue and Volume Forecast, by Container

12.1.5.3. Market Revenue and Volume Forecast, by Application

12.1.5.4. Market Revenue and Volume Forecast, by End User

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by System

12.1.6.2. Market Revenue and Volume Forecast, by Container

12.1.6.3. Market Revenue and Volume Forecast, by Application

12.1.6.4. Market Revenue and Volume Forecast, by End User

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by System

12.2.2. Market Revenue and Volume Forecast, by Container

12.2.3. Market Revenue and Volume Forecast, by Application

12.2.4. Market Revenue and Volume Forecast, by End User

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by System

12.2.5.2. Market Revenue and Volume Forecast, by Container

12.2.5.3. Market Revenue and Volume Forecast, by Application

12.2.5.4. Market Revenue and Volume Forecast, by End User

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by System

12.2.6.2. Market Revenue and Volume Forecast, by Container

12.2.6.3. Market Revenue and Volume Forecast, by Application

12.2.6.4. Market Revenue and Volume Forecast, by End User

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by System

12.2.7.2. Market Revenue and Volume Forecast, by Container

12.2.7.3. Market Revenue and Volume Forecast, by Application

12.2.7.4. Market Revenue and Volume Forecast, by End User

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by System

12.2.8.2. Market Revenue and Volume Forecast, by Container

12.2.8.3. Market Revenue and Volume Forecast, by Application

12.2.8.4. Market Revenue and Volume Forecast, by End User

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by System

12.3.2. Market Revenue and Volume Forecast, by Container

12.3.3. Market Revenue and Volume Forecast, by Application

12.3.4. Market Revenue and Volume Forecast, by End User

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by System

12.3.5.2. Market Revenue and Volume Forecast, by Container

12.3.5.3. Market Revenue and Volume Forecast, by Application

12.3.5.4. Market Revenue and Volume Forecast, by End User

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by System

12.3.6.2. Market Revenue and Volume Forecast, by Container

12.3.6.3. Market Revenue and Volume Forecast, by Application

12.3.6.4. Market Revenue and Volume Forecast, by End User

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by System

12.3.7.2. Market Revenue and Volume Forecast, by Container

12.3.7.3. Market Revenue and Volume Forecast, by Application

12.3.7.4. Market Revenue and Volume Forecast, by End User

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by System

12.3.8.2. Market Revenue and Volume Forecast, by Container

12.3.8.3. Market Revenue and Volume Forecast, by Application

12.3.8.4. Market Revenue and Volume Forecast, by End User

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by System

12.4.2. Market Revenue and Volume Forecast, by Container

12.4.3. Market Revenue and Volume Forecast, by Application

12.4.4. Market Revenue and Volume Forecast, by End User

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by System

12.4.5.2. Market Revenue and Volume Forecast, by Container

12.4.5.3. Market Revenue and Volume Forecast, by Application

12.4.5.4. Market Revenue and Volume Forecast, by End User

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by System

12.4.6.2. Market Revenue and Volume Forecast, by Container

12.4.6.3. Market Revenue and Volume Forecast, by Application

12.4.6.4. Market Revenue and Volume Forecast, by End User

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by System

12.4.7.2. Market Revenue and Volume Forecast, by Container

12.4.7.3. Market Revenue and Volume Forecast, by Application

12.4.7.4. Market Revenue and Volume Forecast, by End User

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by System

12.4.8.2. Market Revenue and Volume Forecast, by Container

12.4.8.3. Market Revenue and Volume Forecast, by Application

12.4.8.4. Market Revenue and Volume Forecast, by End User

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by System

12.5.2. Market Revenue and Volume Forecast, by Container

12.5.3. Market Revenue and Volume Forecast, by Application

12.5.4. Market Revenue and Volume Forecast, by End User

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by System

12.5.5.2. Market Revenue and Volume Forecast, by Container

12.5.5.3. Market Revenue and Volume Forecast, by Application

12.5.5.4. Market Revenue and Volume Forecast, by End User

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by System

12.5.6.2. Market Revenue and Volume Forecast, by Container

12.5.6.3. Market Revenue and Volume Forecast, by Application

12.5.6.4. Market Revenue and Volume Forecast, by End User

Chapter 13. Company Profiles

13.1. Johnson & Johnson, Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Aptar Pharma Group

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. GlaxoSmithKline Plc

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Aegis Therapeutics LLC

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. H&T Presspart Manufacturing Ltd.

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. AstraZeneca Plc

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Becton, Dickinson and Company

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Novartis AG

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Teleflex Incorporated

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Vectura Group Plc.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global intranasal drug delivery devices market was valued at USD 1.52 billion in 2023 and is predicted to reach USD 4.41 billion by 2034.

The global intranasal drug delivery devices market is growing at a CAGR of 10% during the forecast period 2025 to 2034.

Factors such as growing patient preference for nasal drug delivery and increasing popularity of self-administration of medicationsare driving the growth of intranasal drug delivery devices market.High incidence of cardiovascular disorders, increased cancer and diabetes cases, amplified focus on elderly and pediatric patients, and growing demand for home-based healthcare devices are further propelling the intranasal drug delivery devices market expansion across the globe. Additional aspects that are anticipated to fuel this industryare rapid R&D activity and reception of new drug delivery approaches and equipment’s, reformulation of injections and oral medications into the preparations to be administered by the nasal route, and quick onset of action. The simple administration and improved e

North America dominated the global market with a market share of more than 37%.

Asia Pacific is anticipated to grow at the maximum CAGR of around 14% in the forecast period due to high incidence of cancer.

The major companies operating in the worldwide intranasal drug delivery devices market are Johnson & Johnson, Inc., Aptar Pharma Group, GlaxoSmithKline Plc, Aegis Therapeutics LLC, H&T Presspart Manufacturing Ltd., AstraZeneca Plc, Becton, Dickinson and Company, Novartis AG, Teleflex Incorporated, and Vectura Group Plc. among others.

Hospitals accounted for the largest revenue in the end-user segment. High frequency of intranasal drug delivery in hospitals is the key reason for high market share of hospitals.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client